Is the 24.2% figure the trial's main result?
No. The primary end point of the retatrutide Phase 2 trial was the percentage body-weight change at week 24 (Jastreboff et al., NEJM, 2023; ClinicalTrials.gov NCT04881760). The least-squares means at that point were -7.2% in the lowest trial arm, -12.9% and -17.3% in the two combined middle levels, and -17.5% in the highest. Placebo was -1.6%. The week-48 values across those same groups were -8.7%, -17.1%, -22.8% and -24.2%, against -2.1% with placebo. Those later figures were registered as a secondary end point.
A primary end point is the main question a trial is designed and powered to answer. A secondary end point adds context. It does not become the main question just because its number is larger. The -24.2% figure travels furthest online for that very reason.
The paper reports combined results for each pair of groups that reached the same level by different routes. The record we could open does not give a separate result for each of those groups (Jastreboff et al., NEJM, 2023).


